Business · 26/03/2007Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for NOVOLOG Patent Extension
Summary
The Food and Drug Administration has officially confirmed the review period for NOVOLOG's patent extension application, as mandated by law, following a submission to the US Department of Commerce's Director of Patents and Trademarks.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →